// IP Marketing video - START// IP Marketing video - END

Drug that targets cancer in a radically different way approved in U.S.

Drug that targets cancer in a radically different way approved in U.S.

PanARMENIAN.Net - The US Food and Drug Administration has approved a drug for a wide range of cancers based on a shared mutation, rather than the tumors' locations - an advance for the sometimes controversial field of "precision medicine", Sceince Alert reports.

The medication, called Vitrakvi, is the second treatment to receive FDA clearance based on a common biomarker found in an array of cancers. The drug, also called larotrectinib, was approved simultaneously for adults and children.

Typically, oncology drugs are considered much later for children.

Last year the agency, for the first time, approved an immunotherapy drug for tumors with a specific genetic signature, regardless of where they originated in the body. But that treatment had been cleared for several cancers, including advanced melanoma.

The drug is for patients with advanced solid tumors containing what's called an NTRK gene fusion, a hybrid of two genes that can promote uncontrolled cell growth.

Cancers of the thyroid, lung, and head and neck, among others, can be caused by the defect.

The drug is for patients whose cancer has spread or who would experience severe complications by undergoing surgery and have no satisfactory alternatives.

 Top stories
French actor of Armenian descent Charles Gérard died September 19 at the age of 96, Figaro reports.
Archaeological relics related to the Kingdom of Urartu (860 BC – 590 BC) has recently been found in Anaqizli mount.
On land where once stood a cherished church that Sara Corning may have attended, a statue of her now stands.
The integration program initialed by the countries in early September is designed for a year and a half.
Partner news